All AbMole products are for research use only, cannot be used for human consumption.

LY333531 hydrochloride competitively and reversibly inhibits PKCβI and PKCβII (IC50 values are 4.7 and 5.9 nM respectively). Selective for PKCβ over other PKC isozymes (IC50 values are 0.052, 0.25, 0.30, 0.36, 0.60 and >100 μM for PKCη, -δ, -γ, -α, -ε and -ζ respectively). LY333531 exhibits ATP dependent competitive inhibition of PKC beta I and is selective for PKC in comparison to other ATP dependent kinases (protein kinase A, calcium calmodulin, caesin kinase, src tyrosine kinase).
J Mol Cell Cardiol. 2015 Oct;138-47.
Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses.
LY333531 hydrochloride purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | HUVECs |
| Preparation method | Western blot Aortas and HUVECs were lysed in lysis buffer or membrane and cytosol protein extraction kit and total proteins in the supernatant were extracted to perform Western blot analysis. Equal amounts of proteins were separated through electrophoresis on SDS-PAGE gels and transferred to nitrocellulose membranes. After blocked with 5% skim milk, the membranes were incubated with the appropriate primary antibodies respectively against PKC-β, and β-actin with recommended dilution at 4°C overnight. The membranes were washed and further incubated with corresponding secondary antibodies [Anti-Rabbit IgG; Anti-mouse IgG] with horseradish peroxidase (HRP) conjugation at 37 °C for 60 min. The films were developed using an ECL Plus chemiluminescence reagent kit and visualized using ChemiDocXRS. Densitometries were analyzed using Quantity One software. |
| Concentrations | 5µM |
| Incubation time | 24h |
| Animal Experiment | |
|---|---|
| Animal models | Male Sprague-Dawley rats diabetes models |
| Formulation | dissolved in citrate buffer (0.1 mol/L, pH 4.5) |
| Dosages | 1 mg/kg/day |
| Administration | oral gavage for 4 weeks |
| Molecular Weight | 505.01 |
| Formula | C28H28N4O3.HCl |
| CAS Number | 169939-93-9 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PKC Products |
|---|
| Enzastaurin
Enzastaurin inhibits PKCβ, PKCα, PKCγ and PKCε with IC50's of 0.006, 0.039, 0.083 and 0.110 µM, respectively. |
| Go 6983
Go 6983 is a fast acting, lipid soluble, broad spectrum protein kinase C inhibitor. |
| Staurosporine
Staurosporine (AM-2282) is a potent ATP-competitive kinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively. |
| Zoledronic acid
Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects. |
| Dequalinium Chloride
Dequalinium Chloride is a PKC inhibitor with IC50 of 7-18 μM, and also a selective blocker of apamin-sensitive K+ channels with IC50 of 1.1 μM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
